Novo Nordisk A/S
VerifiedGlobal healthcare company with 95 years of innovation and leadership in diabetes care
Bagsværd Capital Region of Denmark (HQ)
Deals in the last 12 months undisclosed
Corporate Venture Fund: Novo Ventures, Novo Holdings
RELATED LANDSCAPES AND LISTS
Company information
Edit Launch date
Employees
Market cap
DKK1.4t
Net debt
DKK459.0b
Firm valuation
$212.0b (Public information from 2022)
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 14.9b | 14.9b | 16.3b | 16.9b | 18.6b | 20.5b |
| % growth | - | - | - | 9 % | 4 % | 10 % | 10 % |
| EBITDA | - | 7.0b | 6.8b | 7.8b | 8.0b | 8.7b | 9.6b |
| % EBITDA margin | - | 47 % | 46 % | 48 % | 47 % | 47 % | 47 % |
| Profit | - | 5.1b | 5.2b | 5.2b | 5.6b | 6.3b | 6.7b |
| % profit margin | - | 34 % | 35 % | 32 % | 33 % | 34 % | 33 % |
| EV / revenue | - | 7.2x | 6.2x | 7.4x | 7.8x | 10.3x | 9.4x |
| EV / EBITDA | - | 15.4x | 13.6x | 15.5x | 16.4x | 22.1x | 20.0x |
| R&D budget | 2.0b | 1.9b | 1.8b | 1.7b | - | - | - |
| R&D % of revenue | - | 13 % | 12 % | 11 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
| N/A | N/A | IPO Not yet verified | |
| Total Funding | - | ||
Recent News about Novo Nordisk A/S
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit